NovoCure Limited Receives $26.93 Consensus Price Target

Analysts give the medical device company a 'Hold' rating on average.

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

NovoCure Limited (NASDAQ:NVCR), a global oncology company pioneering Tumor Treating Fields (TTFields) therapy, has received an average price target of $26.93 from the seven analysts currently covering the stock. The analysts have also assigned the company a 'Hold' rating on average.

Why it matters

NovoCure's TTFields therapy is a novel anti-mitotic treatment for solid tumors, offering an alternative modality to complement existing cancer therapies. The consensus price target and rating from analysts provide insight into the market's perception of the company's growth potential and the challenges it may face.

The details

The seven analysts covering NovoCure have provided a range of recommendations, with one issuing a 'Sell' rating, three assigning 'Hold' ratings, and three giving 'Buy' ratings. The average 1-year price target of $26.93 represents a potential upside of around 106% from the stock's current trading price of $13.04.

  • NovoCure reported its latest quarterly earnings on February 26, 2026.

The players

NovoCure Limited

A global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors.

Wedbush

An investment bank that has reaffirmed a 'neutral' rating and issued a $18.00 target price on NovoCure shares.

HC Wainwright

An investment bank that has boosted its price target on NovoCure from $47.00 to $49.00 and maintained a 'buy' rating.

Evercore

An investment bank that has set a $20.00 price target on NovoCure shares.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.